GlaxoSmithKline will form a big data partnership with Guangzhou Institute of Respiratory Diseases (GIRD) to develop a respiratory disease management system that will target both asthma and chronic obstructive pulmonary disease (COPD). The goal will be to optimize care plans, especially for rural settings. The studies will include reimbursement systems, and they will also pay attention to China's tiered healthcare system, apparently allocating specific tasks to the appropriate levels.
